Open Access
and pathological parameters may increase our ability to determine more accurately which patients may harbor aggressive disease and thus require early intervention. Before this is widely adopted, a few important points need to be raised: (1) this is a retrospective study. A well-controlled prospective study is required to validate the results; (2) this is a single institutional study by a large, well-known tertiary referral center so the potential for bias exists. A larger study involving multiple institutions in different geographic regions with diverse patient populations will provide stronger evidence of the utility of serum lipid profiles in patient management.
In addition to serving as potential novel preoperative biomarkers, the study also provides support to the significance of lipid metabolism in the etiology and biology of prostate cancer. Obesity, physical inactivity, high-fat diet, and dyslipidemia have been considered risk factors for prostate cancer. Prostate cancer cells tend to up-regulate de novo lipid synthesis which may contribute to the uncontrolled proliferation of cancer cells. If we consider low-grade, indolent prostate cancer as a normal aging process that occurs in a significant portion of aged men, there may exist different biologic pathways that lead to the development of aggressive prostate cancer, a truly life-threatening disease. Future studies will further pinpoint the exact role of lipids in this disease process.
Although serum-based biomarkers remain a useful research direction, validation of any novel biomarkers and their widespread adoption will take a significant amount of time, effort and resources. On the other hand, improving the radiologic detection of prostate cancer and targeted biopsy of prostate cancer will likely yield more immediate benefits. There has been significant advancement in the detection of prostate cancer, particularly those of high grade and/or high volume, by multiparametric magnetic resonance imaging (MRI). Although MRI-guided biopsy remains an option, targeted biopsy of the prostate using MRI-ultrasound fusion technology appears more practical. 2 With continuous improvement in the technology, we may eventually be able to detect clinically relevant diseases while ignoring indolent ones, resulting in more optimal management strategy for men diagnosed with prostate cancer.
